ECC 2015: GIOTRIF ® (afatinib) demonstrates superior survival compared to Tarceva® (erlotinib) for patients with previously treated advanced squamous cell carcinoma of the lung, independent of EGFR mutation status

ECC 2015: GIOTRIF ® (afatinib) demonstrates superior survival compared to Tarceva® (erlotinib) for patients with previously treated advanced squamous cell carcinoma of the lung, independent of EGFR mutation status
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news